权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Bioengineering a cortical microtissue model to study human microglia in Alzheimer's disease

生物工程皮质微组织模型来研究阿尔茨海默病中的人类小胶质细胞

基本信息

批准号：
10630949
负责人：
David Allenson Borton
金额：
$ 18.64万
依托单位：
BROWN UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10630949
关键词：
3-Dimensional APP-PS1 Acute Affect Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease pathology Alzheimer&apos s disease therapeutic Amyloidosis Animals Award Behavior Biological Assay Biological Models Biology Biomedical Engineering Brain Characteristics Chimera organism Communities Cues Custom Data Set Development Disease Dissociation Elements Engineering Engraftment Future Gene Expression Generations Genetic Genetic Transcription Genotype Goals Growth Health Human Hybrids Image In Vitro Inflammatory Intervention Knowledge Label Light Link Lipopolysaccharides Mechanics Meta-Analysis Methodology Methods Microglia Mission Modeling Molds Monitor Morphology Mus Mutation Neonatal Nerve Degeneration Neurodegenerative Disorders Neurons Organoids Outcome Pathogenesis Pathogenicity Pathologic Pathology Patients Phenotype Physiological Prevention strategy Property Public Health Publishing Rat Strains Rat Transgene Rattus Research Rest Science Sorting Support System System Techniques Testing Therapeutic Tissue Model Tissues Transgenic Organisms Transplantation United States National Institutes of Health V717F brain cell cell type cost effective design disability falls fighting glial activation improved in vivo induced pluripotent stem cell innovation mutant neural neuroinflammation operation programs reconstitution response scaffold stem cells tau Proteins three dimensional cell culture tool transcriptomics translational study

项目摘要

PROJECT SUMMARY/ABSTRACT Microglia are highly sensitive to the extrinsic cues from their microenvironment in a context-specific manner and rapidly change around diverse cellular states via intrinsic transcriptional programs. The specific microglial state that contributes to Alzheimer’s Disease (AD) pathology is still illy defined, mostly owing to the longstanding critical need for a reliable and robust modeling tool. In light of the substantial difference between human and mouse microglia, the iPSC-derived human microglia (iMG) have emerged as a rigorous platform to investigate neuroinflammation and AD-linked genetics. A recent transition from 2D to 3D culture systems further enhances the utility of iMG in understanding AD pathogenesis, but technical barriers remain. An improvement to achieve better cellular diversity and functionality in a scalable 3D neural setting will make a desired tool that enables precise monitoring and manipulations of iMG inside a stringently controlled brain-like milieu. Our long-term goal is to understand the pathogenic determinants of neuroinflammation to inform crucial future treatment for AD, via stem cell and engineering innovations. To this end, we propose here to introduce an original 3D culture platform to examine the extrinsic and intrinsic elements of microglial activation in health and in AD, based on patient- derived iMG grown in engineered primary rat cortical microtissues. Leveraging validated AD mutant iPSCs and transgenic AD rats, our overall objectives are to 1) confirm the capability of our hybrid model to recapitulate human-specific, AD-related microglia features and signature and 2) to characterize the ‘ground state’ and neuroinflammatory responses of control and AD iMG under a physiological or pathological microenvironment (i.e. wildtype vs. AD transgenic microtissue). Supported by our preliminary studies, our central hypothesis is that the iMG-microtissue growth system supports maturation and operation of human microglia and can be utilized to detect the nuances in microglial behaviors that may contribute to AD pathogenesis. Our specific aims are to test our working hypotheses that 1) iMG populated in cortical microtissues mimic homeostatic human microglia in vivo and can be phenotyped for microglia-intrinsic manifestations contributed by genotypes, and that 2) iMG maintained in AD mutant microtissues are affected by the AD-promoting extrinsic cues and show disease- associated characteristics. Our expected outcomes are to 1) establish a new-generation in vitro human microglia model system that uniquely allows dissecting the intertwined influences from AD-linked genetics and microenvironment on microglial functions and 2) to acquire a distinctive dataset that would offer a framework to pinpoint critical microglia characteristics for AD. We believe an expansion of this research beyond this award period to characterize in depth the microglial findings uncovered here will ultimately bring a valuable opportunity for the development of much-needed intervention and prevention strategies for AD.

项目总结/摘要小胶质细胞对来自其微环境的外部线索高度敏感，通过内在转录程序在不同的细胞状态周围迅速变化。特定的小胶质细胞状态导致阿尔茨海默病（AD）病理学的因素仍然没有明确的定义，主要是由于长期以来的关键因素，需要一个可靠和强大的建模工具。鉴于人类和老鼠之间的实质性差异小胶质细胞，iPSC衍生的人类小胶质细胞（iMG）已经成为研究小胶质细胞的严格平台。神经炎症和AD连锁遗传学。最近从2D到3D培养系统的转变进一步增强了 iMG在了解AD发病机制中的效用，但技术障碍仍然存在。一个改进，以实现在可扩展的3D神经环境中更好的细胞多样性和功能性将成为一种期望的工具，在严格控制的类脑环境中精确监测和操纵iMG。我们的长期目标是了解神经炎症的致病决定因素，为AD的未来治疗提供重要信息，干细胞和工程创新。为此，我们建议在这里引入一个原创的3D文化平台，根据患者的情况，检查健康和AD中小胶质细胞激活的外在和内在因素，衍生的iMG在工程化的原代大鼠皮质微组织中生长。利用经验证的AD突变iPSC和转基因AD大鼠，我们的总体目标是1）确认我们的杂交模型的能力，人类特异性的AD相关小胶质细胞特征和标记，以及2）表征“基态”，在生理或病理微环境下对照和AD iMG的神经炎症反应 (i.e.野生型对AD转基因微组织）。根据我们的初步研究，我们的中心假设是， iMG-微组织生长系统支持人小胶质细胞的成熟和操作以检测可能导致AD发病机制的小胶质细胞行为的细微差别。我们的具体目标是测试我们的工作假设：1）iMG在皮质微组织中的分布模拟了稳态的人类小胶质细胞在体内，并且可以针对由基因型贡献的小胶质细胞内在表现进行表型分型，以及2）iMG 维持在AD突变体微组织中的细胞受到促进AD的外部线索的影响，并显示疾病- 相关特征。我们的预期结果是：1）建立新一代的体外人类小胶质细胞模型系统，独特地允许解剖AD连锁遗传学的交织影响， 2）获得一个独特的数据集，这将提供一个框架，找出AD的关键小胶质细胞特征我们相信这项研究的扩展超出了这个奖项深入描述此处发现的小胶质细胞研究结果的一段时间将最终带来宝贵的机会制定急需的AD干预和预防策略。